title: Occurrence of Graves' disease during retreatment with interferon-alpha 2a for chronic hepatitis C.
abstract: The present report describes a patient who developed Graves' disease 3 months after inception of retreatment with higher doses of interferon-alpha 2a for chronic hepatitis C, although the initial 6-month treatment caused no serious adverse reactions. Severe hyperthyroidism continued despite discontinuation of interferon-alpha 2a, and the patient was subsequently treated with 131I. This case suggests careful evaluation of the safety of retreatment to prevent manifestation of such a complication in the retreatment of chronic hepatitis C with interferon.
authors.affiliation: Fourth Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya.
authors.forename: M
authors.initials: M
authors.lastname: Wada
authors.forename: W
authors.initials: W
authors.lastname: Hiraizumi
authors.forename: M
authors.initials: M
authors.lastname: Fujimoto
authors.forename: A
authors.initials: A
authors.lastname: Kinugasa
authors.forename: S
authors.initials: S
authors.lastname: Shintani
authors.forename: K
authors.initials: K
authors.lastname: Sawada
authors.forename: T
authors.initials: T
authors.lastname: Shimoyama
authors.forename: M
authors.initials: M
authors.lastname: Suehiro
authors.forename: M
authors.initials: M
authors.lastname: Fukuchi
mesh_terms: D000328:Adult; D002908:Chronic Disease; D005260:Female; D006111:Graves Disease / Q000209:etiology* / Q000378:metabolism; D006526:Hepatitis C / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D011994:Recombinant Proteins; D012008:Recurrence
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins